This research is being done to learn whether drug called itacitinib, which is a novel inflammation- and immune-lowering drug (immunosuppressant), can be given before and after non-myeloablative peripheral blood stem cell transplantation (PBSCT; also known as a 'mini' transplant) to help prevent certain complications such as cytokine release syndrome (CRS) for patients with blood cancers, using peripheral blood from a relative. The investigators will also examine if by using itacitinib the investigators can reduce the duration of MMF (other immune suppressive drug administration posttransplant).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participant deaths
Timeframe: 14 days
Number of participants with grade 3 or higher CRS
Timeframe: 14 days
Number of participants with grade 1-2 CRS that requires additional CRS-directed treatment
Timeframe: 14 days
Number of participants with treatment limiting toxicities by Day 60
Timeframe: 60 days